Cargando…
Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690086/ https://www.ncbi.nlm.nih.gov/pubmed/34950472 http://dx.doi.org/10.1093/ckj/sfab146 |
| _version_ | 1784618610231083008 |
|---|---|
| author | Medina-Pestana, José Teixeira, Cinthia Montenegro Cristelli, Marina Pontello Amiratti, Adriano Luiz Manfredi, Silvia Regina Tedesco-Silva, Helio Covas, Dimas Tadeu |
| author_facet | Medina-Pestana, José Teixeira, Cinthia Montenegro Cristelli, Marina Pontello Amiratti, Adriano Luiz Manfredi, Silvia Regina Tedesco-Silva, Helio Covas, Dimas Tadeu |
| author_sort | Medina-Pestana, José |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8690086 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86900862021-12-22 Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study Medina-Pestana, José Teixeira, Cinthia Montenegro Cristelli, Marina Pontello Amiratti, Adriano Luiz Manfredi, Silvia Regina Tedesco-Silva, Helio Covas, Dimas Tadeu Clin Kidney J Letter to the Editor Oxford University Press 2021-08-17 /pmc/articles/PMC8690086/ /pubmed/34950472 http://dx.doi.org/10.1093/ckj/sfab146 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Letter to the Editor Medina-Pestana, José Teixeira, Cinthia Montenegro Cristelli, Marina Pontello Amiratti, Adriano Luiz Manfredi, Silvia Regina Tedesco-Silva, Helio Covas, Dimas Tadeu Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title | Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title_full | Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title_fullStr | Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title_full_unstemmed | Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title_short | Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study |
| title_sort | clinical impact, reactogenicity and immunogenicity after the first coronavac dose in dialysis patients: a phase iv prospective study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690086/ https://www.ncbi.nlm.nih.gov/pubmed/34950472 http://dx.doi.org/10.1093/ckj/sfab146 |
| work_keys_str_mv | AT medinapestanajose clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT teixeiracinthiamontenegro clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT cristellimarinapontello clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT amirattiadrianoluiz clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT manfredisilviaregina clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT tedescosilvahelio clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy AT covasdimastadeu clinicalimpactreactogenicityandimmunogenicityafterthefirstcoronavacdoseindialysispatientsaphaseivprospectivestudy |